Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1 - 2 μg/mL |
5 μg/mL |
Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Human Brain Tissue Slide(GTX22203) , Human Brain Tissue Lysate(GTX27918)
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
ELOVL6 antibody was raised against a 15 amino acid synthetic peptide near the amino terminus of the human ELOVL6.The immunogen is located within the first 50 amino acids of ELOVL6.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
ELOVL fatty acid elongase 6 , FACE , FAE , LCE
Cellular Localization
Endoplasmic reticulum membrane
Background
Lipogenesis is a key event in the energy storage system and is controlled by the transcription factor sterol regulatory element-binding protein (SREBP)-1. Elongation of very long chain fatty acids protein 6 (ELOVL6) is a member of fatty acyl-CoA elongase gene family that converts palmitic to stearic acid and it has been shown to be a target of SREBP-1, playing an important role in de novo synthesis of long-chain saturated and monosaturated fatty acids in conjunction with fatty acid synthase and stearoyl-CoA desaturase ELOVL6 was predicted to be important for tissue fatty acid composition. Recent studies suggest that inhibition of this elongase could be a new therapeutic approach for ameliorating insulin resistance, diabetes and cardiovascular risks, even in the presence of a continuing state of obesity.
Database
Research Area